Perspectives on in vitro to in vivo extrapolations

Applied In Vitro Toxicology

Volumn 4, Issue 4, 2018, Pages 305-316

  Hartung, Thomas ^a,b  

^a JOHNS HOPKINS BLOOMBERG SCHOOL OF PUBLIC HEALTH   (United States)

^b UNIVERSITY OF KONSTANZ   (Germany)

Author keywords

[No Author keywords available]

Indexed keywords

BIOLOGICAL MARKER;

ADVERSE OUTCOME PATHWAY; ANIMAL MODEL; ANIMAL TESTING ALTERNATIVE; HIGH THROUGHPUT SCREENING; IN VITRO STUDY; IN VIVO STUDY; MICROFLUIDICS; MYCOPLASMA; NONHUMAN; OUTCOME ASSESSMENT; PHENOTYPE; PRACTICE GUIDELINE; PRIORITY JOURNAL; REVIEW; RISK ASSESSMENT; SKIN SENSITIZATION; STAKEHOLDER ENGAGEMENT; TOXICOKINETICS;

EID: 85037043671     PISSN: 23321512     EISSN: 23321539     Source Type: Journal    
DOI: 10.1089/aivt.2016.0026     Document Type: Review

References (115)

1. Bale AS, Kenyon E, Flynn TJ, et al. Correlating in vitro data to in vivo findings for risk assessment. ALTEX 2014:31;79-90.
2. Tsaioun K, Blaauboer BJ, Hartung T. Evidence-based absorption, distribution, metabolism, excretion and toxicity (ADMET) and the role of alternative methods. ALTEX 2016:33;343-358.
3. Krewski D, Acosta D, Jr, Andersen M, et al. Toxicity Testing in the 21st Century: A Vision and a Strategy. J Toxicol Environ Health B Crit Rev 2010:13;51-138.
4. Krewski D, Westphal M, Andersen ME, et al. A framework for the next generation of risk science. Environ Health Perspect 2014:122;796-805.
5. Ankley GT, Bennett RS, Erickson RJ, et al. Adverse outcome pathways: A conceptual framework to support ecotoxicology research and risk assessment. Environ Toxicol Chem 2010:29;730-741.
6. Jaworska J, Hoffmann S. Integrated Testing Strategy (ITS)-Opportunities to better use existing data and guide future testing in toxicology. ALTEX 2010:27; 231-242.
7. Combes RD, Balls M. Integrated testing strategies for toxicity employing new and existing technologies. Altern Lab Anim 2011:39;213-225.
8. OECD. 2016. Integrated Approaches to Testing and Assessment (IATA). www.oecd.org/chemicalsafety/riskassessment/iata-integrated-approaches-to-testing-andassessment. htm (last accessed Dec. 17, 2016).
9. Plant NJ. An introduction to systems toxicology. Toxicol Res 2015:4;9-22.
10. Sturla SJ, Boobis AR, FitzGerald RE, et al. Systems toxicology: From basic research to risk assessment. Chem Res Toxicol 2014:27;314-329.
11. Sauer JM, Hartung T, Leist M, et al. Systems toxicology: The future of risk assessment. Int J Toxicol 2015:34;346-348.
12. Stephens ML, Betts K, Beck NB, et al. The emergence of systematic review in toxicology. Toxicol Sci 2016:152;10-16.
13. Hartung T. Food for thought on animal tests. ALTEX 2008:25;3-9.
14. Hartung T. (2015) Evolution of toxicological science: The need for change. Int J Risk Assess Manage 2017:20; 21-45.
15. Hartung T. Look back in anger-what clinical studies tell us about preclinical work. ALTEX 2013:30;275-291.
16. Hoffmann S, Edler L, Gardner I, et al. Points of reference in validation-The report and recommendations of ECVAM Workshop. Altern Lab Anim 2008:36;343-352.
17. Hartung T. Food for thought on validation. ALTEX 2007:24;67-72.
18. Leist M, Hasiwa M, Daneshian M, et al. Validation and quality control of replacement alternatives-current status and future challenges. Toxicol Res 2012:1;8.
19. Leist M, Hartung T. Inflammatory findings on species extrapolations: Humans are definitely no 70-kg mice. Arch Toxicol 2013:87;563-567.
20. Adriaens E, Barroso J, Eskes C, et al. Retrospective analysis of the Draize test for serious eye damage/eye irritation: Importance of understanding the in vivo endpoints under UN GHS/EU CLP for the development and evaluation of in vitro test methods. Arch Toxicol 2014:88;701-723.
21. Luechtefeld T, Maertens A, Russo DP, et al. Analysis of draize eye irritation testing and its prediction by mining publicly available 2008-2014 REACH data. ALTEX 2016: 33;123-134.
22. Hoffmann S. LLNA variability: An essential ingredient for a comprehensive assessment of non-animal skin sensitization test methods and strategies. ALTEX 2015:32;379-383.
23. Luechtefeld T, Maertens A, Russo DP, et al. Analysis of publically available skin sensitization data from REACH registrations 2008-2014. ALTEX 2016:33;135-148.
24. Dumont C, Barroso J, Matys I, et al. Analysis of the Local Lymph Node Assay (LLNA) variability for assessing the prediction of skin sensitisation potential and potency of chemicals with non-animal approaches. Toxicol In Vitro 2016:34;220-228.
25. Smirnova L, Harris G, Leist M, et al. Cellular resilience. ALTEX 2015:32;247-260.
26. Alberts B, Johnson A, Lewis J, et al. Molecular Biology of the Cell 4th ed. New York: Garland Science; 2002. www.bioon.com/book/biology/mboc/mboc.cgi@code= 220801800040279.htm (last accessed Dec. 18, 2016).
27. Boobis AR, Cohen SM, Dellarco V, et al. IPCS framework for analyzing the relevance of a cancer mode of action for humans. Crit Rev Toxicol 2006:36;781-796.
28. Boobis AR, Doe JE, Heinrich-Hirsch B, et al. IPCS framework for analyzing the relevance of a noncancer mode of action for humans. Crit Rev Toxicol 2008:38; 87-96.
29. Rossini GP, Hartung T. Towards tailored assays for cellbased approaches to toxicity testing. ALTEX 2012:29;359-372.
30. Hartung T. Food for thought on cell culture. ALTEX 2007:24;143-147.
31. Hartung T, Daston G. Are in vitro tests suitable for regulatory use? Toxicol Sci 2009:111;233-237.
32. Olson H, Betton G, Robinson D, et al. Concordance of the toxicity of pharmaceuticals in humans and in animals. Regul Toxicol Pharmacol 2000:32;56-67.
33. Pound P, Ebrahim S, Sandercock P, et al. Where is the evidence that animal research benefits humans? BMJ 2004: 328;514-517.
34. Coecke S, Ahr H, Blaauboer BJ, et al. Metabolism: A bottleneck in in vitro toxicological test development. Altern Lab Anim 2006:34;49-84.
35. Kleensang A, Vantangoli M, Odwin-DaCosta S, et al. Genetic variability in a frozen batch of MCF-7 cells invisible in routine authentication affecting cell function. Sci Rep 2016:6;28994.
36. Coecke S, Balls M, Bowe G, et al. Guidance on good cell culture practice.Altern Lab Anim 2005:33;261-287.
37. Stacey GN, Hartung T. Availability, standardization and safety of human cells and tissues for drug screening and testing. In: Drug Testing In Vitro: Breakthroughs and Trends in Cell Culture Technology. U Marx, V Sandig (eds); pp. 231-250.Weinheim:WILEY-VCH Verlag; 2007.
38. Pamies D, Bal-Price A, Simeonov A, et al. Good cell culture practice for stem cells and stem-cell-derived models. ALTEX 2017:34;95-132.
39. OECD, 2016 Draft guidance document on Good In Vitro Method Practices (GIVIMP) for the development of in vitro methods for regulatory use in human safety assessment. www.oecd.org/env/ehs/testing/OECD-Draft-GIVIMP- in-Human-Safety-Assessment.pdf (last accessed Dec. 14, 2016).
40. Hartung T. 3D-A new dimension of in vitro research. Advanced Drug Delivery Reviews, Preface Special Issue "Innovative tissue models for in vitro drug development," 2014:69;vi.
41. Alépée N, Bahinski T, Daneshian M, et al. State-of-The-art of 3D cultures (organs-on-A-chip) in safety testing and pathophysiology-A t4 report. ALTEX 2014:31;441-477.
42. Hartung T, Leist M. Food for thought on the evolution of toxicology and phasing out of animal testing. ALTEX 2008:25;91-96.
43. Leist M, Hartung T, Nicotera P. The dawning of a new age of toxicology. ALTEX 2008:25;103-114.
44. Hartung T. Toxicology for the twenty-first century. Nature 2009:460;208-212.
45. Hartung T. From alternative methods to a new toxicology. Eur J Pharm Biopharm 2011:77;338-349.
46. Willett C, Caverly Rae J, Goyak KO, et al. Building shared experience to advance practical application of pathwaybased toxicology: Liver toxicity mode-of-action. ALTEX 2014:31;500-519.
47. Hartung T, McBride M. Food for thoughton mapping the human toxome. ALTEX 2011:28;83-93.
48. AndersenM, BettsK,DraganY, et al. Developing microphysiological systems for use as regulatory tools-challenges and opportunities. ALTEX 2014:31;364-367. Extended online version www.altex.ch/resources/altex-2014-3-Suppl- Andersen.pdf (last accessed June 11, 2017).
49. Hartung T, Zurlo J. Alternative approaches for medical countermeasures to biological and chemical terrorism and warfare. ALTEX 2012:29;251-260.
50. NRC-National Research Council, Committee on Animal Models for Assessing Countermeasures to Bioterrorism Agents. Animal Models for Assessing Countermeasures to Bioterrorism Agents. Washington, DC: The National Academies Press; 2011, pp. 1-153. http://dels.national academies.org/Report/Animal-Models-Assessing-Counter measures/13233 (last accessed June 11, 2017).
51. Hogberg HT, Bressler J, Christian KM, et al. Toward a 3D model of human brain development for studying gene/environment interactions. Stem Cell Res Ther 2013:4 (Suppl 1) S4;1-7.
52. Pamies D, Hartung T, Hogberg HT. Biological and medical applications of a brain-on-A-chip. Exp Biol Med 2014: 239;1096-1107.
53. Pamies D, Barreras P, Block K, et al. A Human Brain Microphysiological System derived from iPSC to study central nervous system toxicity and disease. ALTEX 2017 [Epub ahead of print]. doi: 10.14573/altex.1609122. www.altex.ch/resources/epub-Pamies2-of-161128-v2.pdf (last accessed Dec. 13, 2016).
54. Smirnova L, Hogberg HT, Leist M, et al. Developmental neurotoxicity-challenges in the 21st century and in vitro opportunities. ALTEX 2014:31;129-156.
55. Marx U, Andersson TB, Bahinski A, et al. Biologyinspired microphysiological system approaches to solve the prediction dilemma of substance testing using animals. ALTEX 2016:33;272-321.
56. Smirnova L, Harris G, Delp J, et al. A LUHMES 3D dopaminergic neuronal model for neurotoxicity testing allowing long-term exposure and cellular resilience analysis. Arch Toxicol 2016:90;2725-2743.
57. Tsaioun K, Blaauboer BJ, Hartung T. Evidence-based absorption, distribution, metabolism, excretion and toxicity (ADMET) and the role of alternative methods. ALTEX 2016:33;343-358.
58. Bouvier d'Yvoire M, Prieto P, Blaauboer BJ, et al. Physiologically-based Kinetic Modelling (PBK Modelling): Meeting the 3Rs Agenda. The Report and Recommendations of ECVAM Workshop 63. Altern Lab Anim 2007:35;661-671.
59. Basketter DA, Clewell H, Kimber I, et al. A roadmap for the development of alternative (non-animal) methods for systemic toxicity testing. ALTEX 2012:29;3-89.
60. Leist M, Hasiwa N, Rovida C, et al. Consensus report on the future of animal-free systemic toxicity testing. ALTEX 2014:31;341-356.
61. Ferrario D, Hartung T. Glossary of reference terms for alternative test methods and their validation. ALTEX 2014:31; 319-335.
62. Blaauboer BJ, Boekelheide K, Clewell HJ, et al. The use of biomarkers of toxicity for integrating in vitro hazard estimates into risk assessment for humans. ALTEX 2012:29;411-425.
63. Adverse Outcome Pathway Wiki. https://aopwiki.org (last accessed Dec. 19, 2016).
64. Effectopedia. www.qsari.org/index.php/software/100- effectopedia (last accessed Dec. 19, 2016).
65. Patlewicz G, Ball N, Becker RA, et al. Read-across approaches- Misconceptions, promises and challenges ahead. ALTEX 2014:31;387-396.
66. Hartung T. Making big sense from big data in toxicology by read-across. ALTEX 2016:33;83-93.
67. Ball N, CroninMTD,Shen J, et al.TowardGoodRead-Across Practice (GRAP) guidance. ALTEX 2016:33;149-166.
68. Human Toxome Project. http://humantoxome.com (last accessed Dec. 19, 2016).
69. Bouhifd M, Hogberg HT, Kleensang A, et al. Mapping the Human Toxome by systems toxicology. Basic Clin Pharm Toxicol 2014:115;1-8.
70. Kleensang A, Maertens A, Rosenberg M, et al. Pathways of toxicity. ALTEX 2014:31;53-61.
71. Hartung T, Stephens M, Hoffmann S. Mechanistic validation. ALTEX 2013:30;119-130.
72. Hartung T, Stephens M. Toxicity testing in the 21st Century, approaches to implementation. In: Encyclopedia of Toxicology 3rd ed. P Wexler (ed); pp. 673-675. London: Elsevier Inc., Academic Press.
73. Hartung T. Lessons learned from alternative methods and their validation for a new toxicology in the 21st century. J Toxicol Environ Health 2010:13;277-290.
74. Davis M, Boekelheide K, Boverhof DR, et al. The new revolution in toxicology: The good, the bad, and the ugly. Ann N Y Acad Sci 2013:1278;11-24.
75. van Vliet E, Danesian M, Beilmann M, et al. Current approaches and future role of high content imaging in safety sciences and drug discovery. ALTEX 2014:31; 479-493.
76. Tollefsen KE, Scholz S, Cronin MT, et al. Applying adverse outcome pathways (AOPs) to support integrated approaches to testing and assessment (IATA). Regul Toxicol Pharmacol 2015:70;629-640.
77. Corvi R, Ahr H-J, Albertini S, et al. Validation of toxicogenomics-based test systems: ECVAM-ICCVAM/NICEATM considerations for regulatory use. Environ Health Perspect 2006:114;420-429.
78. Johansson H, Albrekt A-S, Borrebaeck CAK, et al. The GARD assay for assessment of chemical skin sensitizers. Toxicol In Vitro 2013:27;1163-1169.
79. Cottrez F, Boitel E, Auriault C, et al. Genes specifically modulated in sensitized skins allow the detection of sensitizers in a reconstructed human skin model. Development of the SENS-IS assay. Toxicol In Vitro 2015:29; 787-802.
80. Bouhifd M, Hartung T, Hogberg HT, et al. Review: Toxicometabolomics. J Appl Toxicol 2013:33;1365-1383.
81. Ramirez T, Daneshian M, Kamp H, et al. Metabolomics in toxicology and preclinical research. ALTEX 2013:30; 209-225.
82. Maertens A, Luechtefeld T, Kleensang A, et al. MPTP's pathway of toxicity indicates central role of transcription factor SP1. Arch Toxicol 2015:89;743-755.
83. Krug AK, Gutbier S, Zhao L, et al. Transcriptional and metabolic adaptation of human neurons to the mitochondrial toxicant MPP+. Cell Death Dis 2014:5;e1222.
84. Begley CG, Ellis LM. Drug development: Raise standards for preclinical cancer research. Nature 2012:483;531-533.
85. Prinz F, Schlange T, Asadullah K. Believe it or not: How much can we rely on published data on potential drug targets? Nat Rev Drug Disc 2011:10;712-712.
86. Hartung T, Luechtefeld T, Maertens A, et al. Integrated testing strategies for safety assessments. ALTEX 2013:30:3-18.
87. Hartung T. A toxicology for the 21st century: Mapping the road ahead. Toxicol Sci 2009:109;18-23.
88. Rovida C, Alépée N, Api AM, et al. Integrated testing strategies (ITS) for safety assessment. ALTEX 2015:32; 25-40.
89. Jaworska J, Harol A, Kern PS, et al. Integrating non-animal test information into an adaptive testing strategy - skin sensitization proof of concept case. ALTEX 2011:28;211-225.
90. Hartung T, van Vliet E, Jaworska J, et al. Systems toxicology. ALTEX 2012:29;119-128.
91. Hartung T, FitzGerald R, Paul J, Miriams G, Peitsch M, Rostami-Hodjegan A, Shah I, Wilks M, and Sturla S. Systems toxicology - Real world applications and opportunities. Chemical Research in Toxicology 2017:30; 870-882.
92. Hartung T. Food for thought.on evidence-based toxicology. ALTEX 2009:26;75-82.
93. Neugebauer EA, Holaday JW. Handbook of Mediators in Septic Shock 1st ed. Boca Raton, Florida: CRC-Press; 1993, pp. 1-608. www.ebtox.org (last accessed Dec. 19, 2016).
94. Hoffmann S, Stephens M, Hartung T. Evidence-based toxicology. In: Encyclopedia of Toxicology 3rd ed. vol 2. P Wexler (ed); pp. 565-567. London: Elsevier Inc., Academic Press; 2014.
95. Ruden C. The use and evaluation of primary data in 29 trichloroethylene carcinogen risk assessments. Regul Toxicol Pharmacol 2001:34;3-16.
96. Hoffmann S, Hartung T. Diagnosis: Toxic!-Trying to apply approaches of clinical diagnostics and prevalence in toxicology considerations. Toxicol Sci 2005:85;422-428.
97. Hoffmann S, Hartung T. Towards an evidence-based toxicology. Hum Exp Toxicol 2006:25;497-513.
98. Griesinger C,Hoffmann S, Kinsner-Ovaskainen A, et al. Proceedings of the first international forum towards evidencebased toxicology. Conference Centre Spazio Villa Erba, Como, Italy. 15-18 October 2007. Human and Experimental Toxicology, Special Issue: Evidence-Based Toxicology (EBT) 2009:28;81-163.
99. Schneider K, Schwarz M, Burkholder I, et al. "ToxRTool", a new tool to assess the reliability of toxicological data. Toxicol Lett 2009:189;138-144.
100. Hartung T. Evidence based-toxicology-The toolbox of validation for the 21st century? ALTEX 2010:27;241-251.
101. Stephens ML, Andersen M, Becker RA, et al. Evidencebased toxicology for the 21st century: Opportunities and challenges. ALTEX 2013:30;74-104.
102. Stephens ML, Betts K, Beck NB, et al. (2016). The emergence of systematic review in toxicology. Toxicol Sci 2016:152:10-16.
103. Hoffmann S, de Vries RBM, Stephens ML, et al. A primer on systematic reviews in toxicology. Archives of Toxicology 2017, in press. DOI 10.1007/s00204-017-1980-3, available online: Https://link.springer.com/article/10.1007/s00204-017-1980-3.
104. Hartung T, Bremer S, Casati S, et al. A modular approach to the ECVAM principles on test validity. Altern Lab Anim 2004:32;467-472.
105. Corvi R, Albertini S, Hartung T, et al. ECVAM retrospective validation of in vitro micronucleus test (MNT). Mutagenesis 2008:23;271-283.
106. Samuel GO, Hoffmann S, Wright R, et al. Guidance on assessing the methodological and reporting quality of toxicologically relevant studies: A scoping review. Environ Int 2016:92-93;630-646.
107. Judson R, Kavlock R, Martin M, et al. Perspectives on validation of high-throughput pathway-based assays supporting the 21st century toxicity testing vision. ALTEX 2013:30;51-66.
108. Hartung T. Food for thoughton alternative methods for chemical safety testing. ALTEX 2010:27;3-14.
109. Hartung T. Food for thoughton alternative methods for nanoparticle safety testing. ALTEX 2010:27;87-95.
110. Hartung T, Sabbioni E. Alternative in vitro assays in nanomaterial toxicology. WIREs Nanomed Nanobiotechnol 2011:3;545-573.
111. Silbergeld EK, Contreras EQ, Hartung T, et al. Nanotoxicology: "the end of the beginning"-Signs on the roadmap to a strategy for assuring the safe application and use of nanomaterials. ALTEX 2011:28;236-241.
112. Bottini AA, Hartungm T. Food for thoughton economics of animal testing. ALTEX 2009:26;3-16.
113. Taleb NN. The black swan-The impact of the highly improbable. New York: The Random House Publishing Group; 2007.
114. Hartung T, Hoffmann S. Food for thought on.. in silico methods in toxicology. ALTEX 2009:26;155-166.
115. Maertens A, Anastas N, Spencer PJ, et al. Green Toxicology. ALTEX 2014:31;243-249.